Using Real-World Evidence to Achieve High Quality Care that Improves Payer Outcomes for Multiple Sclerosis

Learn About:

The impact and unique challenges of health equity in MS
How current and emerging therapies impact disease control
How the value of real-world evidence is interpreted to inform appropriate access

Expert Faculty Presenters:


	Marie LeGrand, MPH Associate Vice President, Mission Delivery, Health Equity & Education Multiple Sclerosis Association of America (MSAA) Click here for biography

	Dana McCormick, RPh, FAMCP Director of Pharmacy Blue Cross Blue Shield of Texas Click here for biography

	Mitzi Joi Williams, MD, FAAN Founder and CEO Joi Life Wellness Group Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
Multiple sclerosis (MS) onset typically occurs in the prime of life, between the ages of 20 and 40 years, with women affected approximately twice as often as men. MS is the leading cause of non-traumatic disability in young adults. This webcast highlights opportunities for managed care and specialty pharmacy professionals to enhance disease state knowledge and administrative competencies to manage health plan patients with MS resulting in optimal clinical and economic outcomes.

Educational Objectives
After completing this activity, the participant should be better able to:

Review the impact of health equity and the unique challenges presented by MS in diverse patient populations
Assess how current and emerging therapies impact disease control in diverse patient populations and their fit into the MS treatment algorithm
Interpret the value of real-world evidence to inform appropriate access and reimbursement decisions for patients with MS
Illustrate collaborative treatment optimization approaches to balance costs with improved outcomes for the management of MS

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-23-109-L01-P
Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Disclosure of Relevant Financial Relationships
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

*Name of Working Group Members/Planners*	*Reported Financial Relationship*
Marie LeGrand, MPH	Nothing to disclose
Dana McCormick, RPh, FAMCP	Nothing to disclose
Mitzi Joi Williams, MD, FAAN	Consultant, Advisor, Speaker – Biogen, EMD Serono, Genentech, TG Therapeutics, Bristol Myers Squibb, Janssen, Novartis, Sanofi Genzyme, Alexion

The PACE planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.